Population Pharmacokinetc/Pharmacodynamic Modeling of Paclitaxel and Carboplatin in Ovarian Cancer

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-07-5049
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Paclitaxel-Carboplatin Chemotherapy Induced Hematologic Toxicities Among Epithelial Ovarian Cancer Patients

Universa Medicina
2016English

Multifunctional Nanoparticles for Co-Delivery of Paclitaxel and Carboplatin Against Ovarian Cancer by Inactivating JMJD3-HER2 Axis

Nanoscale
Materials ScienceNanotechnologyNanoscience
2017English

Cisplatin/Carboplatin Cross-Resistance in Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
1989English

Rectal Perforation Following Paclitaxel and Carboplatin Chemotherapy for Advanced Ovarian Cancer: A Case Report and Review of the Literature

Journal of Medical Case Reports
Medicine
2018English

Preoperative Conformal Radiotherapy Concurrently With Paclitaxel/Carboplatin in Gastric Cancer

Journal of Cancer Therapy
2018English

Clinical Trials and Progress With Paclitaxel in Ovarian Cancer

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2010English

Population Pharmacokinetic-Pharmacodynamic Modeling of Captopril in Healthy Volunteers

Journal of Korean Society for Clinical Pharmacology and Therapeutics
2001English

Vorinostat Increases Carboplatin and Paclitaxel Activity in Non-Small Cell Lung Cancer Cells

International Journal of Cancer
Cancer ResearchOncology
2010English

Dose-Finding and Sequencing Study of Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy